XClose

UCL Queen Square Institute of Neurology

Home
Menu

Current trials list across Queen Square

Brain Repair & Rehabilitation
Short TitleFull TitlePI PhaseType
INSPIRES-2Improving sleep and learning in rehabilitation after stroke, part 2.Ajina,  SaraNot ApplicableNon-commercial non-portfolio
ECST 2: The 2nd European Carotid Surgery TrialECST 2: The 2nd European Carotid Surgery TrialBrown, Prof MartinNot ApplicableNon-commercial portfolio
CONVINCE - Protocol Version 2.1 29th November 2016CONVINCE - COLchicine for preventioN of Vascular Inflammation in Non-CardioEmbolic stroke) - a randomised clinical trial of low-dose colchicine for secondary prevention after stroke.Chandratheva, Dr ArvindPhase IIINon-commercial portfolio
Protocol 18-513 Andexanet ICHA PHASE 4 RANDOMIZED CLINICAL TRIAL OF ANDEXANET ALFA [ANDEXANET ALFA FOR INJECTION] IN ACUTE INTRACRANIAL HEMORRHAGE IN PATIENTS RECEIVING AN ORAL FACTOR XA INHIBITORChandratheva, Dr ArvindPhase IVCommercial portfolio
Mechanisms underlying spoken language productionMechanisms underlying spoken language production: facilitating frontal brain networks following aphasic strokeCrinion, Dr JennyNot ApplicableNon-commercial non-portfolio
Natural history and biomarkers in autonomic disordersNatural history and biomarkers in autonomic disordersIodice, Dr ValeriaNot ApplicableNon-commercial non-portfolio
ATTENDATTEND: Attentional Therapy for the TrEatment of Neglect Disorder (ATTEND).Leff, Prof AlexanderNot ApplicableNon-commercial portfolio
PLORAS version 1Predicting Language Outcome and Recovery After StrokeLeff, Prof AlexanderNot ApplicableNon-commercial portfolio
Neural correlates of visual consciousnessThe neural correlates of conscious visual experience in normal and brain damaged human subjectsLeff, Prof AlexanderNot ApplicableNon-commercial non-portfolio
Digital Interventions in Neuro-Rehabilitation (DINR)Digital Interventions in Neuro-Rehabilitation: Two digital neuro interventions (DNIs)for word retrieval. The development and testing of two web-based therapy applications for people with naming difficulties caused by Stroke (iTALKbetter) or Mild-Moderate Dementia (Gotcha!)Leff, Prof AlexanderStudyNon-commercial non-portfolio
BPL-PSILOAn Exploratory Open-Label, Phase 1b, Ascending Dose Study to Evaluate the Effects of Oral 3 [2 (dimethylamino)ethyl]-1h-indol-4-yl (Psilocybin, BPL PSILO) on Cognition in Patients With Chronic Short-Lasting Unilateral Neuralgiform Headache Attacks (SUNHA)Matharu, Dr ManjitPhase IbCommercial portfolio
Headache and facial pain: a prospective clinical studyPrimary and secondary headaches and facial pain disorders: a prospective clinical studyMatharu, Dr ManjitNot ApplicableNon-commercial non-portfolio
BASIC StudyBASIC - Botulinum toxin type A blockade of the sphenopalatine ganglion in treatment-refractory chronic cluster headache Matharu, Dr ManjitPhase IIINon-commercial portfolio
Craniocervical imaging in joint hypermobility disorders (version 1)Headache disorders and imaging of the craniocervical junction in joint hypermobility disordersMatharu, Dr ManjitNot ApplicableNon-commercial portfolio
Cytokines in chronic headache disordersCytokines and inflammatory biomarkers in chronic headache and facial pain disordersMatharu, Dr ManjitNot ApplicableNon-commercial non-portfolio
Lesion Function MappingHigh-Dimensional Lesion-Function Mapping of the Human BrainNachev, Dr ParashkevStudyNon-commercial non-portfolio
Neurophysiology evaluation of symptomatic sacral Tarlov cystsA comprehensive evaluation of the effects of sacral Tarlov cysts on pelvic organ functions and neurophysiological parameters of the pelvic floorPanicker, Dr JaleshNot ApplicableNon-commercial non-portfolio
MultiStem® Administration for Stroke Treatment and Enhanced RecoveryMultiStem® Administration for Stroke Treatment and Enhanced Recovery Study (MASTERS-2)Perry, Dr RichardPhase IIICommercial portfolio
Study Exploring The Impact of COVID-19 On Stroke (SETICOS)Study Exploring The Impact of COVID-19 On Stroke (SETICOS)Perry, Dr RichardNot ApplicableNon-commercial portfolio
ATTEST 2Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST 2)Perry, Dr RichardPhase IIINon-commercial portfolio
Validation Of Bioarray In Stroke Validation Of Bioarray In Stroke (VOBIS).Perry, Dr RichardNot ApplicableCommercial portfolio
Mechanisms underlying limb apraxiaUnderstanding motor processing pathways to guide therapy for limb apraxiaPerry, Dr RichardNot ApplicableNon-commercial portfolio
252LH301: Efficacy & Safety of IV BIIB093 (The CHARM Study)Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema following Large Hemispheric InfarctionPerry, Dr RichardPhase IIICommercial portfolio
PERCIVALPeriodontitis, COVID-19 and Cerebrovascular DiseaseSimister, Dr RobertNot ApplicableNon-commercial portfolio
Prehospital triage for stroke patients (PHOTONIC) (v1.0)PreHOspital Triage for potential stroke patients: lessONs from systems Implemented in response to COVID19 (PHOTONIC)Simister, Dr RobertNot ApplicableNon-commercial portfolio
TEMPO-2Multicentre, prospective randomized open label, blinded-endpoint (PROBE) controlled trial of thrombolysis with low dose Tenecteplase (TNK-tPA) versus standard of care in the prevention of disability at 3 months in minor ischemic stroke with proven acute symptomatic occlusionSimister, Dr RobertPhase IIINon-commercial portfolio
prophylaxis of post-stroke epilepsyprevention of epilepsy in stroke patients at high risk of developing unprovoked seizures: anti-epileptogenic effects of eslicarbazepine acetateSimister, Dr RobertPhase IICommercial portfolio
Biomarkers of early stroke recovery (BEST) study. Version 2.Biomarkers of early stroke recovery (BEST)Ward, Prof NickNot ApplicableNon-commercial portfolio
INTENSIVEIs intensive upper limb rehabilitation effective in chronic stroke patients? A randomised controlled trial Ward, Prof NickNot ApplicableNon-commercial portfolio
TRACS studyTracking Reticulospinal And Corticospinal pathways after Stroke TRACS studyWard, Prof NickNot ApplicableNon-commercial non-portfolio
tDCS in post-stroke fatigue (TIPS)Does diminished motor cortical excitability cause post-stroke fatigue?Ward, Prof NickNot ApplicableNon-commercial portfolio
MOtor Control After Stroke (MOCAS)Does the upper limb rehabilitation programme lead to a general improvement in motor control processes in chronic stroke patients?Ward, Prof NickNot ApplicableAcademic/student
STROKE ODYSSEYS Version 1Evaluation of an interdisciplinary performance arts intervention that combines movement and voice to reduce anxiety
and depression among those living with the effects of a stroke.
Ward, Prof NickNot ApplicableNon-commercial non-portfolio
Re-opening the Critical Period after Stroke (ReCAPS). Version 1.0Re-opening the critical period for plasticity after stroke with dose-controlled non-invasive brain stimulation Ward, Prof NickNot ApplicableNon-commercial portfolio
TICH-3Tranexamic acid for Hyperacute Spontaneous Intracerebral Haemorrhage (TICH-3) Werring, Dr DavidPhase IIINon-commercial portfolio
ENRICH-AF: Edoxaban for IntraCranial Haemorrhage survivors with AFEdoxabaN foR IntraCranial Haemorrhage survivors with atrial fibrillation (ENRICH-AF)Werring, Dr DavidPhase IIINon-commercial portfolio
PROHIBIT-ICHPrevention Of Hypertensive Injury to the Brain by Intensive Treatment after Intracerebral Haemorrhage: a pilot randomised trial of home telemetry-guided treatmentWerring, Dr DavidNot ApplicableNon-commercial portfolio
Genetic risk factors for cerebral small vessel diseaseGenetic risk factors for cerebral small vessel diseaseWerring, Dr DavidNot ApplicableNon-commercial portfolio
Familial Cerebral Small Vessel DiseaseA UK Familial Cerebral Small Vessel Disease StudyWerring, Dr DavidNot ApplicableNon-commercial portfolio
Tenecteplase in Wake-up Ischaemic Stroke TrialTenecteplase in Wake-up Ischaemic Stroke Trial (TWIST)Werring, Dr DavidPhase IIINon-commercial portfolio
Prediction of stroke outcome using brain imaging machine-learningOptimizing prediction of stroke outcome using brain imaging machine-learningWerring, Dr DavidNot ApplicableNon-commercial portfolio
OPTIMAS TrialOPtimal TIMing of Anticoagulation after acute ischaemic Stroke: a randomised controlled trial (OPTIMAS Trial)Werring, Dr DavidNot ApplicableNon-commercial portfolio
R4VaDRates, Risks and Routes to Reduce Vascular Dementia (R4VaD)Werring, Dr DavidNot ApplicableNon-commercial portfolio

 

Imaging Neuroscience
Short titleLong titlePIPhaseType
Development of novel MRI techniques for neurological applicationsDevelopment of novel MRI techniques for neurological applicationsWheeler-Kingshott, Prof ClaudiaNot ApplicableNon-commercial portfolio
MODEL-COVAdvanced Modeling Of Magnetic Resonance Imaging Data To Study The
Biophysical Underpinning Of NEurological Symptoms Of Long-COVID
Wheeler-Kingshott, Prof ClaudiaNot ApplicableNon-commercial portfolio

 

Neurodegenerative Disease
Short titleLong titlePIPhaseType
Memory, language and complex thinking skillsMemory, language and complex thinking skills in people with and without neurological conditionsCipolotti, Prof LisaNot ApplicableNon-commercial non-portfolio
Cognitive dysfunction in survivors of childhood medulloblastomaNeuroanatomical correlates of cognitive dysfunction in short- and long-term survivors of childhood medulloblastomaClark,  ChrisNot ApplicableNon-commercial portfolio
Neuropsychology of posterior cortical atrophy version1Neuropsychological investigation of visuospatial and literacy skills in posterior cortical atrophyCrutch, Prof SebastianNot ApplicableNon-commercial non-portfolio
DIANDominantly Inherited Alzheimer’s networkFox, Prof NickNot ApplicableNon-commercial portfolio
A novel cell model for the dementiasInduced pluripotent stem cells derived from patients with familial Alzheimer's disease and other dementias as novel cell models for neurodegenerationFox, Prof NickNot ApplicableNon-commercial portfolio
Longitudinal research into Alzheimer’s disease and other dementiasLongitudinal research into Alzheimer’s disease and other dementiasFox, Prof NickNot ApplicableNon-commercial non-portfolio
Normal Pressure Hydrocephalus SILKStable Isotope Labeling Kinetics in Normal Pressure Hydrocephalus: implications for neurodegenerationFox, Prof NickNot ApplicableNon-commercial portfolio
DREAMS START (Dementia RElAted Manual for Sleep) RCTA parallel multi-centre randomised controlled trial to determine the clinical and cost-effectiveness of DREAMS START (Dementia RElAted Manual for Sleep; STrAtegies for RelaTives)for people living with dementia and their carersFox, Prof NickNot ApplicableNon-commercial portfolio
ADDIDADDID: ADDitonal csf In DementiaFox, Prof NickStudyNon-commercial non-portfolio
hMRI in Alzheimer’s Disease Non-Invasive In-Vivo Histology in Alzheimer’s disease Using Magnetic Resonance Imaging (MRI)Fox, Prof NickNot ApplicableNon-commercial portfolio
Tau targeted vaccines in patients with early Alzheimer’s DiseaseA Phase Ib/IIa Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Immunogenicity of Different Doses, Regimens and Combinations of Tau Targeted Vaccines in Subjects with Early Alzheimer’s DiseaseMummery, Dr Catherine Phase I/IICommercial portfolio
Phase 3 Study of AL001 in Patients with or at risk of FTDA Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of AL001 in Individuals at Risk for or With Frontotemporal Dementia Due to Heterozygous Mutations in the Progranulin GeneMummery, Dr Catherine Phase IIICommercial portfolio
221AD304 - Phase 3 Study of Aducanumab in Early Alzheimer’s DiseasePhase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects with Alzheimer’s disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205.Mummery, Dr Catherine Phase IIICommercial portfolio
DIANTU001:Ph. II/III Randomized, Double-blind Placebo in Alzheimer'sA Phase II/III Randomized, Double-Blind,Placebo-Controlled Multi-Center Study of 2 Potential Disease Modifying Therapies in Individuals at Risk for and with Dominantly Inherited Alzheimer’s DiseaseMummery, Dr Catherine Phase II/IIINon-commercial portfolio
AL002 In Participants With Early Alzheimer's DiseaseA Phase 2 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of AL002 in Participants with Early Alzheimer’s DiseaseMummery, Dr Catherine Phase IICommercial portfolio
Study E2814-G000-103An Open-Label Phase 1b/2 Study to Assess Safety and Target Engagement of E2814 in Subjects with Mild to Moderate Cognitive Impairment due to Dominantly Inherited Alzheimer’s Disease Mummery, Dr Catherine Phase I/IICommercial portfolio
Biomarkers and Rapid Imaging in Dementia Diagnosis: B-RAPIDD Biomarkers and Rapid Imaging in Dementia Diagnosis: B-RAPIDD Mummery, Dr Catherine Not ApplicableNon-commercial portfolio
ALN-APP-001A Study to Evaluate the Safety and Tolerability of ALN-APP in
Patients with EOAD
Mummery, Dr Catherine Phase ICommercial portfolio
IBC-01-01A First in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IBC-Ab002 in Persons with Early Alzheimer's DiseaseMummery, Dr Catherine Phase ICommercial portfolio
CONFLuid studyHealthy control biofluid study.Paterson, Dr RossNot ApplicableNon-commercial non-portfolio
IRAS 276517 A Phase 1/2 Ascending Dose Study to Evaluate the SafetyA Phase 1/2 Ascending Dose Study to Evaluate the Safety and Effects on
Progranulin Levels of PR006A in Patients with Fronto-Temporal Dementia
with Progranulin Mutations (FTD-GRN)
Rhorer , Dr Jonathan Phase I/IICommercial portfolio
GENFI Mindstrong studyGenetic Frontotemporal Dementia Initiative Mindstrong studyRohrer, Dr JonathanNot ApplicableNon-commercial non-portfolio
Genetic Frontotemporal dementia Initiative (GENFI)Genetic Frontotemporal dementia Initiative (GENFI)Rohrer, Dr JonathanNot ApplicableNon-commercial portfolio
Depletion of Serum Amyloid P Component in Alzheimer's Disease (v1.0)DEpletion of Serum amyloid P component In Alzheimer’s Disease: DESPIAD. Double-blind placebo controlled randomised phase IIb trial of SAP depletion by CPHPC in mild Alzheimer’s disease.Rossor, Prof MartinPhase IINon-commercial portfolio
Bedside Assessment of Eye Movements in the Cognitively Impaired V1.1Comparison of Bedside Assessment of Eye Movements using Facial and Non-facial Stimuli in the CognitivelyRossor, Prof MartinNot ApplicableNon-commercial non-portfolio
Shared decision aid nutrition/hydration in dementia in acute hospitalsDeveloping a shared decision aid regarding nutrition and hydration for people with severe dementia in acute hospitalsSampson, Dr ElizabethNot ApplicableNon-commercial non-portfolio
Shared decision aid nutrition/hydration in dementia in acute hospitalsDeveloping a shared decision aid regarding nutrition and hydration for people with severe dementia in acute hospitalsSampson, Dr ElizabethNot ApplicableNon-commercial non-portfolio
Multi-centre MRI study of Post Mortem proven cases (Research Database)Multi-centre MRI study of Post Mortem proven cases (Research Database)Schott, Dr JonathanNot Applicable 
CSF collection in patients with neurodegenerative diseasesCerebrospinal fluid collection in patients with neurodegenerative diseasesSchott, Dr JonathanNot ApplicableNon-commercial portfolio
Biomarkers and genetics in cognitive disordersBiomarkers and genetics in cognitive disordersSchott, Dr JonathanNot ApplicableNon-commercial portfolio
MRC National Survey of Health and Development Neuroimaging substudyMRC National Survey of Health and Development Neuroimaging substudySchott, Dr JonathanNot ApplicableNon-commercial portfolio
Brain signature of auditory information processingBrain signature of auditory information processing in the degenerative dementiasWarren, Dr JasonNot ApplicableNon-commercial portfolio
Cognitive outcomes in Phenylketonuria across agesCognitive assessment of Phenylketonuria: Comparing outcomes across developmental agesAitkenhead,  LynneNot ApplicableNon-commercial portfolio
Pompe RegistryPompe Registry; ongoing, observational database tracking the natural history and outcomes of patients with pompe diseaseLachmann, Dr RobinNot ApplicableCommercial non-portfolio
MRS I Registry online Feb 2006MRS I Registry; ongoing, observational database tracking natural history and outcomes of patients with MPS ILachmann, Dr RobinNot ApplicableCommercial non-portfolio
Gaucher Registry, online feb 2006Gaucher Registry, online feb 2006Lachmann, Dr RobinNot ApplicableCommercial non-portfolio
Rare and Undiagnosed Diseases Study  (RUDY)Rare and Undiagnosed Diseases Study (RUDY)Lachmann, Dr RobinNot ApplicableNon-commercial portfolio
Open Label Extension study (OLE) of the Modify studyA multi-center, open-label, uncontrolled, single-arm, extension study to determine the long-term safety and tolerability of oral lucerastat in adult subjects with Fabry diseaseLachmann, Dr RobinPhase IIICommercial portfolio
Cognitive outcomes in Phenylketonuria when returning to dietAssessing possible cognitive, emotional and quality of life benefits of resuming a diet in adults with PKULachmann, Dr RobinNot ApplicableNon-commercial portfolio
Gaucherite- A study to classify Gaucher diseasePredictive measures to stratify clinical outcomes in children and adults with Gaucher disease and responses to specific therapiesLachmann, Dr RobinNot ApplicableNon-commercial portfolio
INPDRInternational Niemann-Pick Disease RegistryLachmann, Dr RobinNot ApplicableNon-commercial portfolio
Phase 2 study of ARCT-810 in Participants with OTC DeficiencyPhase 2, Randomized, Double-Blind, Placebo-Controlled, Nested Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ARCT-810 in Adolescent and Adult Participants with Ornithine Transcarbamylase DeficiencyLachmann, Dr RobinPhase IICommercial portfolio
CHIL 5604Arimoclomol prospective double blind, randomised, placebo-controlled study in patients diagnosed with Niemann Pick disease type CLachmann, Dr RobinPhase II/IIICommercial portfolio
XLH Registry An international, multicentre, prospective, non-interventional observational registry for patients with X-linked hypophosphatemia (XLH)Murphy, Dr ElaineNot ApplicableCommercial portfolio
E IMDEuropean registry and network for intoxication type metabolic diseasesMurphy, Dr ElaineNot ApplicableNon-commercial non-portfolio
Homocystinuria v1.0A Phase 1/2 Multiple Ascending-Dose Study in Subjects With Homocystinuria Due to Cystathionine β-Synthase (CBS) Deficiency to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of ACN00177Murphy, Dr ElainePhase I/IICommercial portfolio
CHIL3751 (110-504)Morquio A Registry StudyMurphy, Dr ElaineNot ApplicableCommercial portfolio
RAPSODI GDRemote assessment of Parkinsonism supporting ongoing development of interventions in Gaucher's diseaseMurphy, Dr ElaineNot ApplicableNon-commercial portfolio
Longitudinal Physiological Changes in Inherited Metabolic DisordersLongitudinal study of aerobic capacity and skeletal muscle characteristics in patients with rare inherited metabolic disorders (IMD)Murphy, Dr ElaineNot ApplicableNon-commercial non-portfolio
LALDRAn Observational Disease and Clinical Outcomes Registry of Patients with Lysosomal Acid Lipase (LAL) DeficiencyMurphy, Dr ElaineNot ApplicableCommercial portfolio
GalNet RegistryEuropean Galactosemia Network Patient Registry (GalNET) (Version 1)Murphy, Dr Elaine Non-commercial non-portfolio
Development of methods for diagnosis of neurometabolic disordersMetabolomic profiling of cerebrospinal fluid to improve diagnosis and treatment monitoring of patients with inborn or acquired errors of metabolismPope, Dr Simon  
Memory, language and complex thinking skillsMemory, language and complex thinking skills in people with and without neurological conditionsCipolotti, Prof LisaNot ApplicableNon-commercial non-portfolio
Cognitive dysfunction in survivors of childhood medulloblastomaNeuroanatomical correlates of cognitive dysfunction in short- and long-term survivors of childhood medulloblastomaClark,  ChrisNot ApplicableNon-commercial portfolio
Neuropsychology of posterior cortical atrophy version1Neuropsychological investigation of visuospatial and literacy skills in posterior cortical atrophyCrutch, Prof SebastianNot ApplicableNon-commercial non-portfolio
DIANDominantly Inherited Alzheimer’s networkFox, Prof NickNot ApplicableNon-commercial portfolio
A novel cell model for the dementiasInduced pluripotent stem cells derived from patients with familial Alzheimer's disease and other dementias as novel cell models for neurodegenerationFox, Prof NickNot ApplicableNon-commercial portfolio
Longitudinal research into Alzheimer’s disease and other dementiasLongitudinal research into Alzheimer’s disease and other dementiasFox, Prof NickNot ApplicableNon-commercial non-portfolio
Normal Pressure Hydrocephalus SILKStable Isotope Labeling Kinetics in Normal Pressure Hydrocephalus: implications for neurodegenerationFox, Prof NickNot ApplicableNon-commercial portfolio
DREAMS START (Dementia RElAted Manual for Sleep) RCTA parallel multi-centre randomised controlled trial to determine the clinical and cost-effectiveness of DREAMS START (Dementia RElAted Manual for Sleep; STrAtegies for RelaTives)for people living with dementia and their carersFox, Prof NickNot ApplicableNon-commercial portfolio
ADDIDADDID: ADDitonal csf In DementiaFox, Prof NickStudyNon-commercial non-portfolio
hMRI in Alzheimer’s Disease Non-Invasive In-Vivo Histology in Alzheimer’s disease Using Magnetic Resonance Imaging (MRI)Fox, Prof NickNot ApplicableNon-commercial portfolio
Tau targeted vaccines in patients with early Alzheimer’s DiseaseA Phase Ib/IIa Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Immunogenicity of Different Doses, Regimens and Combinations of Tau Targeted Vaccines in Subjects with Early Alzheimer’s DiseaseMummery, Dr Catherine Phase I/IICommercial portfolio
Phase 3 Study of AL001 in Patients with or at risk of FTDA Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of AL001 in Individuals at Risk for or With Frontotemporal Dementia Due to Heterozygous Mutations in the Progranulin GeneMummery, Dr Catherine Phase IIICommercial portfolio
221AD304 - Phase 3 Study of Aducanumab in Early Alzheimer’s DiseasePhase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects with Alzheimer’s disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205.Mummery, Dr Catherine Phase IIICommercial portfolio
DIANTU001:Ph. II/III Randomized, Double-blind Placebo in Alzheimer'sA Phase II/III Randomized, Double-Blind,Placebo-Controlled Multi-Center Study of 2 Potential Disease Modifying Therapies in Individuals at Risk for and with Dominantly Inherited Alzheimer’s DiseaseMummery, Dr Catherine Phase II/IIINon-commercial portfolio
AL002 In Participants With Early Alzheimer's DiseaseA Phase 2 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of AL002 in Participants with Early Alzheimer’s DiseaseMummery, Dr Catherine Phase IICommercial portfolio
Study E2814-G000-103An Open-Label Phase 1b/2 Study to Assess Safety and Target Engagement of E2814 in Subjects with Mild to Moderate Cognitive Impairment due to Dominantly Inherited Alzheimer’s Disease Mummery, Dr Catherine Phase I/IICommercial portfolio
Biomarkers and Rapid Imaging in Dementia Diagnosis: B-RAPIDD Biomarkers and Rapid Imaging in Dementia Diagnosis: B-RAPIDD Mummery, Dr Catherine Not ApplicableNon-commercial portfolio
ALN-APP-001A Study to Evaluate the Safety and Tolerability of ALN-APP in
Patients with EOAD
Mummery, Dr Catherine Phase ICommercial portfolio
IBC-01-01A First in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IBC-Ab002 in Persons with Early Alzheimer's DiseaseMummery, Dr Catherine Phase ICommercial portfolio
CONFLuid studyHealthy control biofluid study.Paterson, Dr RossNot ApplicableNon-commercial non-portfolio
IRAS 276517 A Phase 1/2 Ascending Dose Study to Evaluate the SafetyA Phase 1/2 Ascending Dose Study to Evaluate the Safety and Effects on
Progranulin Levels of PR006A in Patients with Fronto-Temporal Dementia
with Progranulin Mutations (FTD-GRN)
Rhorer , Dr Jonathan Phase I/IICommercial portfolio
GENFI Mindstrong studyGenetic Frontotemporal Dementia Initiative Mindstrong studyRohrer, Dr JonathanNot ApplicableNon-commercial non-portfolio
Genetic Frontotemporal dementia Initiative (GENFI)Genetic Frontotemporal dementia Initiative (GENFI)Rohrer, Dr JonathanNot ApplicableNon-commercial portfolio
Depletion of Serum Amyloid P Component in Alzheimer's Disease (v1.0)DEpletion of Serum amyloid P component In Alzheimer’s Disease: DESPIAD. Double-blind placebo controlled randomised phase IIb trial of SAP depletion by CPHPC in mild Alzheimer’s disease.Rossor, Prof MartinPhase IINon-commercial portfolio
Bedside Assessment of Eye Movements in the Cognitively Impaired V1.1Comparison of Bedside Assessment of Eye Movements using Facial and Non-facial Stimuli in the CognitivelyRossor, Prof MartinNot ApplicableNon-commercial non-portfolio
Shared decision aid nutrition/hydration in dementia in acute hospitalsDeveloping a shared decision aid regarding nutrition and hydration for people with severe dementia in acute hospitalsSampson, Dr ElizabethNot ApplicableNon-commercial non-portfolio
Shared decision aid nutrition/hydration in dementia in acute hospitalsDeveloping a shared decision aid regarding nutrition and hydration for people with severe dementia in acute hospitalsSampson, Dr ElizabethNot ApplicableNon-commercial non-portfolio
Multi-centre MRI study of Post Mortem proven cases (Research Database)Multi-centre MRI study of Post Mortem proven cases (Research Database)Schott, Dr JonathanNot Applicable 
CSF collection in patients with neurodegenerative diseasesCerebrospinal fluid collection in patients with neurodegenerative diseasesSchott, Dr JonathanNot ApplicableNon-commercial portfolio
Biomarkers and genetics in cognitive disordersBiomarkers and genetics in cognitive disordersSchott, Dr JonathanNot ApplicableNon-commercial portfolio
MRC National Survey of Health and Development Neuroimaging substudyMRC National Survey of Health and Development Neuroimaging substudySchott, Dr JonathanNot ApplicableNon-commercial portfolio
Brain signature of auditory information processingBrain signature of auditory information processing in the degenerative dementiasWarren, Dr JasonNot ApplicableNon-commercial portfolio
Genomic and expression profiling of brain tumoursGenomic and expression profiling of brain tumoursBrandner, Prof SebastianNot ApplicableNon-commercial non-portfolio

HD Gene TRX2

Safety and Efficacy of AMT-130 in European Adults With Early Manifest Huntington's Disease

Tabrizi, Prof Sarah/ Wild, Prof Edward

Phase I/II

Commercial non-portfolio

PIVOT-HD

A Study to Evaluate the Safety and Efficacy of PTC518 in Participants With Huntington's Disease

Tabrizi, Prof Sarah

Phase II

Commercial non-portfolio

Generation HD2

A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease.

Tabrizi, Prof Sarah

Phase II

Commercial non-portfolio

Enroll-HD

A Prospective Registry Study in Global Huntington’s Disease Cohort

Tabrizi, Prof Sarah

Not applicable

Non-Commercial portfolio

HD Clarity

A Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington’s Disease

Wild, Prof Edward

Not Applicable

Non-Commercial portfolio

HD-YAS 2.0

Huntington’s Disease Young Adult Study 2.0

Tabrizi, Prof Sarah

Not Applicable

Non-Commercial portfolio

 

Neuromuscular Diseases
Short titleLong titlePIPhaseType
Ultrasound to detect vocal fold movement in neurological diseaseA feasibility study to investigate the accuracy and viability of ultrasound in detecting impairments of vocal fold mobility in people with neurological diseaseAllen, Dr JodiNot ApplicableNon-commercial non-portfolio
Skeletal Muscle Dysfunction in Aortic StenosisInvestigating Skeletal Muscle Dysfunction in Aortic StenosisAstin, Dr RonanNot ApplicableNon-commercial non-portfolio
ReSolve v.1.1Clinical Trial Readiness to Solve Barriers to Drug Development in FSHDBugiardini, Dr EnricoNot ApplicableNon-commercial non-portfolio
1821-FSH-301A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled,
48-Week, Parallel-Group Study of the Efficacy and Safety of Losmapimod
in Treating Patients with Facioscapulohumeral Muscular Dystrophy
Bugiardini, Dr EnricoPhase IIICommercial portfolio
ADHEREA Phase 2 Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Carr, Dr AislingPhase IICommercial portfolio
ARDAA Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, Multicenter Trial to Evaluate the Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 2 Dose Regimens of ARGX-117 in Adults With Multifocal Motor NeuropathyCarr, Dr AislingPhase IICommercial portfolio
SORDA RandomIzed, Double-Blind, Placebo-CoNtrolled, Two-Part Study to Evaluate the Pharmacodynamic EffIcacy and Clinical Benefit of AT 007 in Patients with SoRbitol Dehydrogenase (SORD) Deficiency.Cortese, Dr Andrea Commercial portfolio
SBMA Natural history studyNatural history study of Spinal and Bulbar Muscular AtrophyFratta, Dr PietroNot ApplicableNon-commercial non-portfolio
MND GENETICSNext Generation Genetic Screening in Motor Neuron DiseaseFratta, Dr PietroNot ApplicableNon-commercial portfolio
A Multicentre Biomarker Study in NeurodegenerationA Multicentre Biomarker Study in NeurodegenerationFratta, Dr PietroNot ApplicableNon-commercial portfolio
Investigation of human ion channel disordersInvestigation of human neurological ion channel or episodic neurological disordersHanna, Prof MichaelNot ApplicableNon-commercial portfolio
Molecular mechanisms in mitochondrial diseaseInvestigation of nuclear and mitochondrial genes underlying mitochondrial and muscle-related genetic diseasesHanna, Prof MichaelPilot/FeasibilityNon-commercial non-portfolio
Biobank to facilitate future therapy of neuromuscular disorders. Setting up of a rare diseases biological samples bank (biobank) for research to facilitate pharmacological, gene and cell therapy trials in neuromuscular disorders (NMD)Hanna, Prof MichaelNot ApplicableNon-commercial non-portfolio
MRI in Motor Neuropathies V1Magnetic Resonance Imaging as an outcome measure in Motor NeuropathiesHanna, Prof MichaelNot Applicable 
Molecular alterations in inclusion body myositisGenetic, transcriptomic and proteomic alterations in inclusion body myositisHanna, Prof MichaelNot ApplicableNon-commercial non-portfolio
International Sporadic Inclusion Body Myositis Genetic StudyUsing Next Generation Sequencing to Unravel the Pathogenesis of Sporadic Inclusion Body Myositis (IBM) International - IBM Consortium Genetic StudyHanna, Prof MichaelNot ApplicableNon-commercial portfolio
ICGNMDINTERNATIONAL CENTRE FOR GENOMIC MEDICINE IN NEUROMUSCULAR DISEASES (ICGNND)Hanna, Prof MichaelNot ApplicableNon-commercial portfolio
MitocohortMedical Research Council Centre for the Neuromuscular diseases: Mitochondrial disease patient cohort studyHanna, Prof MichaelNot ApplicableNon-commercial portfolio
Lupin PASS studyAn Observational Study to Describe the Long-term Safety and Effectiveness of Namuscla in the Symptomatic Management of Myotonia in Adult Patients with Non-dystrophic Myotonic DisordersHanna, Prof MichaelNot ApplicableCommercial non-portfolio
mitoPK[11C]PK11195 PET as a biomarker to diagnose and monitor natural history in mitochondrial diseaseHanna, Prof MichaelNot ApplicableNon-commercial non-portfolio
Nicotinamide Riboside in mitochondrial biogenesisTo study the role of nicotinamide riboside in inducing mitochondrial biogenesisHanna, Prof MichaelNot ApplicableNon-commercial portfolio
Activity & sedentary behaviour in channelopathy and Myotonic DystrophyMeasuring activity and sedentary behaviour in people with Muscle Ion Channelopathy and Myotonic Dystrophy type 1, and assessing the use of individual goal setting to support increasing habitual physical activity activity.Holmes, Miss SarahNot ApplicableNon-commercial non-portfolio
UK register for hereditary spastic paraplegiaUK register for hereditary spastic paraplegiaHoulden, Prof HenryNot ApplicableNon-commercial portfolio
 International Genetics Collaboration (IGC)International Genetics Collaboration (IGC): An observational study in the UK only, with international collaborators, to identify disease genes, genetic and COVID-19 risk factors, disease biomarkers and fundamental genetic mechanismsHoulden, Prof HenryNot ApplicableNon-commercial portfolio
MRI in Inflammatory NeuropathiesDiagnostic Magnetic Resonance Imaging Characteristics of Inflammatory NeuropathiesLunn, Prof MichaelNot ApplicableNon-commercial portfolio
International Guillain–Barré Syndrome Outcome StudyClinical and biological determinants of disease course in Guillain-Barré syndrome: a prospective UK-wide observational study interfacing with the International Guillain-Barré syndrome Outcome Study -IGOS.Lunn, Prof MichaelNot ApplicableNon-commercial portfolio
Creation and validation of biomarkers in inflammatory neuropathiesA pilot study to develop and validate biomarkers to monitor disease progression in POEMS syndrome and inflammatory neuropathies using a disability scale designed using Rasch statistics and magnetic resonance imagingLunn, Prof MichaelNot Applicable 
Single molecule biomarker discovery in inflammatory neuropathyA pilot study to identify ultra low concentration biomarkers in the serum of patients with inflammatory neuropathy using the ultrasensitive Single Molecule Analyser (SIMOA) apparatusLunn, Prof MichaelStudyNon-commercial non-portfolio
The pathogenesis of idiopathic sensory ganglionopathyInvestigations into the possible antibody mediated causes of idiopathic sensory ganglionopathyLunn, Prof MichaelNot ApplicableNon-commercial non-portfolio
OPTIC TrialIntravenous immunoglobulin and intravenous methylprednisolone as optimal induction treatment in CIDPLunn, Prof MichaelPhase IIINon-commercial portfolio
Advanced metrology in axial spondyloarthritis (ANDROID) An investigation into the responsiveness of Inertial Measurement Unit (IMU) sensor-based tests in measuring changes in spinal mobility and function in axial spondyloarthritis patients treated with biologic drugsMachado, Dr PedroNot ApplicableNon-commercial portfolio
IBM SwallowEvaluation of dysphagia in inclusion body myositis (IBM)Machado, Dr PedroNot ApplicableNon-commercial non-portfolio
PHOENIXPhase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of AMX0035 Versus Placebo for 48-week Treatment of Adult Patients with Amyotrophic Lateral Sclerosis (ALS)Malaspina, Dr AndreaPhase IIICommercial portfolio
Lighthouse IIRANDOMISED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE 3 TRIAL OF TRIUMEQ IN
AMYOTROPHIC LATERAL SCLEROSIS
Malaspina, Dr AndreaPhase IIINon-commercial portfolio
MYO-Guide: a machine learning approach to the analysis of MRIImplementation of an artificial intelligence module on the online imaging portal MYO-Share for guiding the diagnosis of muscle diseaseMorrow, Dr JasperNot ApplicableNon-commercial non-portfolio
ALS Biomarkers StudyCharacterisation of a panel of disease biomarkers in peripheral blood from individuals with amyotrophic lateral sclerosis/motor neuron diseaseOrrell, Dr RichardNot ApplicableNon-commercial portfolio
An RCT of ACT for people with MNDA randomised controlled trial of acceptance and COMmitment therapy for people with Motor nEuroN Disease (COMMEND)Orrell, Dr RichardNot ApplicableNon-commercial portfolio
Adult SMA REACH Study Adult SMA REACH: Development and implementation of a standardised data set and data collection research study in the UK Adult SMA populationParton, Dr MatthewNot ApplicableNon-commercial portfolio
Clinical Trial Assessing KL1333A Randomised, Double-blind, Parallel-group, Placebo-controlled, Phase Ia/Ib, Multiple-site Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of KL1333 after a Single Oral Dose and Multiple Ascending Oral Doses in Healthy Subjects and Patients with Primary Mitochondrial DiseasePitceathly, Dr RobertPhase ICommercial portfolio
Mitox studyThe effects of oxygen in the context of mitochondrial dysfunctionPitceathly, Dr RobertNot ApplicableNon-commercial portfolio
 Natural History Study of Pyruvate Dehydrogenase DeficiencyNatural History Study of Pyruvate Dehydrogenase Deficiency Pitceathly, Dr RobertNot ApplicableNon-commercial portfolio
Phase 2b Safety and Efficacy Study of REN001 in Mitochondrial MyopathyA double-blind, placebo-controlled, study to evaluate the efficacy and safety of 24 weeks treatment with REN001 in patients with Primary Mitochondrial Myopathy (PMM)Pitceathly, Dr RobertPhase IICommercial portfolio
ION-PROMDevelopment of a patient reported outcome measure (PROM) for patients with

inherited optic neuropathy (ION)
Pitceathly, Dr RobertNot ApplicableNon-commercial portfolio
2020-104A - Abliva - Mitochondrial Disease An interventional, randomised, double-blind, parallel-group, placebo-controlled, flexible-dose, adaptive study of the efficacy of KL1333 in adult patients with primary mitochondrial disease (PMD)Pitceathly, Dr RobertPhase IIICommercial portfolio
REN001-201-DXA, a sub-study of the STRIDE studyAN EXPLORATORY STUDY TO ASSESS CHANGE IN BONE MINERAL DENSITY (BMD) AFTER 24 WEEKS TREATMENT OF REN001 IN SUBJECTS TAKING PART IN THE STRIDE STUDY, USING DUAL-ENERGY X-RAY ABSORPTIOMETRY (DXA)Pitceathly, Dr RobertPhase IICommercial portfolio
Open label study of REN001 in PMM subjectsAn open label, multi-centre study to evaluate the long-term safety and tolerability of REN001 in subjects with primary mitochondrial myopathy (PMM)Pitceathly, Dr RobertPhase IICommercial portfolio
A Phase 1b Open Label Study of REN001 in McArdle DiseaseA PHASE 1B, OPEN-LABEL STUDY TO EVALUATETHE SAFETY AND TOLERABILITY OF 12 WEEKS TREATMENT WITH ORAL REN001 IN PATIENTS WITH MCARDLE DISEASE (GLYCOGEN STORAGE DISORDER TYPE 5)Quinlivan, Prof RosalinePhase ICommercial portfolio
A Natural History Study in Patients with Duchenne Muscular DystrophyA Natural History Study in Patients with Duchenne Muscular Dystrophy Managed in Routine Clinical Practice. Quinlivan, Prof RosalineNot ApplicableCommercial portfolio
Rare Diseases Translational Research- DMDNeuromuscular Rare Disease Translational Research in patients with Duchenne Muscular DystrophyQuinlivan, Prof RosalineNot ApplicableNon-commercial portfolio
MRI in McArdle DiseaseMuscle MRI in patients with McArdle Disease (Glycogen storage disease type V)Quinlivan, Prof RosalineNot ApplicableNon-commercial non-portfolio
Survey about urinary symptoms and renal function in adults with DMDSurvey about the prevalence of urinary symptoms and abnormal renal function in adults with Duchenne muscular dystrophy (DMD) who are on and off glucocorticoids (CSs) treatmentQuinlivan, Prof RosalineNot ApplicableNon-commercial non-portfolio
EDG5506BMDA Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of EDG-5506 on Safety, Biomarkers, Pharmacokinetics, and Functional Measures in Adults and Adolescents with Becker Muscular DystrophyQuinlivan, Prof RosalinePhase IICommercial portfolio
MRI and Gait in dHMNExploring muscle structure, function and gait patterns in people with Distal Hereditary Motor Neuropathy: natural history and the effect of rehabilitation interventions Ramdharry, Dr GitaNot ApplicableNon-commercial non-portfolio
Fatigue in individuals infected with SARS-Cov-2Identifying incidence and nature of Fatigue in Individuals infected with COVID-19 (SARS-Cov-2) in the United KingdomRamdharry, Dr GitaNot ApplicableNon-commercial non-portfolio
ADAPT-NMD studyADAPT NMD: A hybrid II study of the feasibility and implementation of a self-management programme for people with neuromuscular diseasesRamdharry, Dr GitaNot ApplicableNon-commercial portfolio
Supporting Consultations in Remote Physiotherapy (SCiP)Supporting Consultations in Remote Physiotherapy (SCiP): a mixed-methods study to develop guidance for video consultations in physiotherapy servicesRamdharry, Dr GitaNot ApplicableNon-commercial non-portfolio
CMT: A Natural History StudyCharcot-Marie-Tooth Disease and Related Disorders: A Natural History StudyReilly, Prof MaryNot ApplicableNon-commercial portfolio
Preventable Axon Degeneration In Human DiseasePreventable Axon Degeneration In Human DiseaseReilly, Prof MaryNot ApplicableNon-commercial portfolio
Muscle MRI in Charcot-Marie-Tooth Disease (CMT) Muscle MRI in Charcot Marie Tooth Disease: a Prospective Cohort Study Reilly, Prof MaryNot ApplicableNon-commercial portfolio
CMT-TREAT-NMD-IDCharcot Marie Tooth disease Translational Research in Europe for the Assessment and Treatment of Neuromuscular Diseases International Database (CMT-TREAT-NMD-ID)Reilly, Prof MaryNot ApplicableNon-commercial non-portfolio
Endemic neuropathy in UK African and Caribbean communitiesInvestigating the genetic basis of nutritional optic and sensory neuropathy in African and Caribbean communities in the UKRossor, Mr AlexNot ApplicableNon-commercial portfolio
MND Register for England, Wales and Northern IrelandMND Register for England, Wales and Northern IrelandSidle, Dr KatieNot ApplicableNon-commercial portfolio
Immune Profiles in Myasthenia GravisComparison of lymphocyte subset, cytokine, and complement profiles in myasthenia gravis of different severity, disease time-points, and treatment historySpillane, Dr JenniferNot ApplicableNon-commercial non-portfolio
Developing antigen specific immunotherapy for myasthenia gravisIdentification of antigen processing independent epitopes for developing antigen specific immunotherapy in myasthenia gravisSpillane, Dr JenniferNot ApplicableNon-commercial portfolio
MEND: MExiletine versus lamotrigine in Non-Dystrophic myotonias A phase III, randomised, double blinded, head-to-head, single-site, cross-over trial of lamotrigine versus mexiletine for non-dystrophic myotonias. Vivekanandam, Dr VinojiniPhase IIINon-commercial portfolio
Neuroimmunology 1.4Investigation of autoimmunity and its effects on the brain 1.4Zandi, Dr MichaelNot ApplicableNon-commercial portfolio
IVIG and rituximab in antibody-associated psychosis - SINAPPS2A randomised phase II double-blinded placebo-controlled trial of intravenous immunoglobulins and rituximab in patients with antibody-associated psychosis (SINAPPS2)Zandi, Dr MichaelPhase IINon-commercial portfolio
END-DM1Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 Turner, Dr ChrisNot ApplicableNon-commercial non-portfolio
DYNE101-DM1-201A Randomized, Placebo-Controlled, Multiple Ascending Dose Study Assessing
Safety, Tolerability, Pharmacodynamics, Efficacy, and Pharmacokinetics of DYNE-101
Administered to Participants with Myotonic Dystrophy Type 1
Turner, Dr ChrisPhase IICommercial portfolio
Understanding Dysphagia in Myotonic Dystrophy Type 1 Version 1.1Understanding Oro-Pharyngeal Dysphagia in Myotonic Dystrophy Type 1 (DM1).Smith, Dr ChristinaNot Applicable 
Experiences of Individuals with Dysphagia and Neuromuscular DiseaseUnderstanding the Experiences and Priorities Individuals Living with Dysphagia due to Neuromuscular DiseaseSmith, Dr ChristinaNot ApplicableNon-commercial non-portfolio
Clinical & Experimental Epilepsy 
Short titleLong titlePIPhaseType
PRISM ProjectThe Prevention and Risk Identification of SUDEP (Sudden Unexpected Death in Epilepsy) Mortality - PRISM ProjectDiehl, Dr BeateNot ApplicableNon-commercial non-portfolio
Optimising cognitive outcomes in epilepsy surgeryOptimising cognitive outcomes in epilepsy surgery with direct cortical stimulation: a pilot, feasibility studyDiehl, Dr Beate Non-commercial non-portfolio
Optimizing epilepsy surgery V1Optimizing epilepsy surgeryDuncan, Prof JohnNot ApplicableNon-commercial portfolio
The 7-TLE StudyThe 7-Tesla Temporal Lobe Epilepsy StudyDuncan, Prof JohnNot ApplicableNon-commercial non-portfolio
Multicentre Epilepsy Lesion Detection Project: a collaborative cohortMulticentre Epilepsy Lesion Detection Project: a collaborative cohort for the analysis of focal epilepsiesDuncan, Prof JohnNot ApplicableNon-commercial non-portfolio
Genetic fMRI studyFMRI study of cognition in patients with idiopathic epilepsies and their siblingsKoepp, Prof Matthias  
Pilot Pharmacological-fMRI StudyPilot Pharmacological fMRI Study - The effects of drugs on cognition in epilepsyKoepp, Prof Matthias Non-commercial non-portfolio
Multimodal imaging of Inflammation in Epileptogenesis and Depression INFLAmmatory pathways in Multi-modal imaging of Epileptogenesis and Depression - a pilot study
(INFLAMED)
Koepp, Prof MatthiasNot ApplicableNon-commercial portfolio
Epilepsy and neurodegeneration: disease mechanisms and early detectionEpiphany: Epilepsy and neurodegeneration: disease mechanisms and early detectionKoepp, Prof MatthiasNot ApplicableNon-commercial non-portfolio
Dopamine release during epileptic seizuresDopamine release and blood flow changes during induced epileptic seizures assessed with simultaneous PET-MR-EEGKoepp, Prof Matthias Non-commercial portfolio
Longitudinal cognitive fMRI: Rehabilitation and Surgery in epilepsyLongitudinal cognitive fMRI: Rehabilitation and Surgery in epilepsySidhu, Dr Meneka Non-commercial non-portfolio
EpiPGXEpilepsy Pharmacogenomics: delivering biomarkers for clinical useSisodiya, Prof Sanjay Non-commercial portfolio
Cortical excitability in genetic neurological disordersCortical excitability in subjects with genetic neurological disorders, a Transcranial Magnetic Stimulation studySisodiya, Prof Sanjay Academic/student
EP-SKINNon-invasive Monitoring of Antiepileptic Drug Levels – A Pilot StudySisodiya, Prof SanjayNot ApplicableNon-commercial portfolio
Epilepsy surgical and post mortem tissue bankEpilepsy (surgical and post mortem) research tissue bank.Thom, Dr Maria Non-commercial non-portfolio
Person centred risk communications about epilepsyPerson centred risk communication - what works best for people with epilepsy and their clinicians (a qualitative study) Walker, Prof MatthewNot ApplicableNon-commercial portfolio
High frequency activity in epilepsy patientsHigh frequency oscillations in epilepsy patients: an intracranial electroencephalography and single unit recording multicase study at the National Hospital for Neurology and NeurosurgeryWalker, Prof Matthew Non-commercial non-portfolio
The use of portable Magnetoencephalography (MEG) in epilepsy. v1.1The use of portable Magnetoencephalography (MEG) in epilepsy. v1.1Walker, Prof Matthew Non-commercial non-portfolio
Multi-centre Epilepsy Lesion Detection (MELD) ProjectMulti-centre Epilepsy Lesion Detection (MELD) ProjectWinston, Dr Gavin Non-commercial non-portfolio
Biomarkers to distinguish epileptic from non-epileptic seizures IIBiomarkers to distinguish epileptic from functional non-epileptic seizures II: Using bio-signals obtained from EEG and non-EEG sensors to distinguish epileptic from functional non-epileptic seizures, an observational studyYogarajah, Dr MahindaNot ApplicableNon-commercial portfolio

 

Neuroinflammation 
Short titleLong titlePIPhaseType
UK MS RegisterThe UK Multiple Sclerosis RegisterBraisher, Mrs Marie Non-commercial portfolio
Safety of IxaZOmib targeting plasma cells in MS (SIZOMUS)Safety of ixazomib targeting plasma cells in multiple sclerosis: A phase 1b randomised, double-blind, placebo-controlled trial.Brownlee, Dr WallacePhase IbNon-commercial portfolio
MS-PROACTIVEPreventing job loss using Acceptance and Commitment Therapy in Vocational Rehabilitation Brownlee, Dr WallaceNot ApplicableNon-commercial portfolio
BN42083 - OCREVUS HIGH DOSE PPMS STUDYA PHASE IIIB MULTICENTER, RANDOMIZED, DOUBLE-BLIND, CONTROLLED STUDY TO
EVALUATE THE EFFICACY, SAFETY AND PHARMACOKINETICS OF A HIGHER DOSE OF OCRELIZUMAB IN ADULTS WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS
Brownlee, Dr WallacePhase IIICommercial portfolio
SATRALIZUMAB IN PATIENTS WITH NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD)A Multicenter, Single Arm, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Satralizumab in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)Brownlee, Dr WallacePhase IIIbCommercial portfolio
CAMELOT-MSCladribine tablets in Highly-Active Relapsing Multiple Sclerosis - Real-World Effectiveness in UK Clinical PracticeBrownlee, Dr WallaceNot ApplicableCommercial non-portfolio
Misdiagnosis of MS in the UKMisdiagnosis of MS in the UKBrownlee, Dr WallaceNot ApplicableNon-commercial non-portfolio
Dynamics of grey matter & white matter pathology in multiple sclerosisThe dynamics and clinical relevance of grey matter and periventricular white matter pathology in multiple sclerosisChard, Dr DeclanNot ApplicableNon-commercial portfolio
MN39158 - A Long Term Extension Study in Multiple SclerosisA SINGLE ARM, OPEN LABEL MULTICENTRE EXTENSION STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB IN PATIENTS WITH MULTIPLE SCLEROSIS PREVIOUSLY ENROLLED IN A F. HOFFMANN-LA ROCHE SPONSORED OCRELIZUMAB PHASE IIIb/IV CLINICAL TRIAL Chataway, Prof JeremyPhase IIICommercial portfolio
OCTOPUS - Optimal Clinical Trials Platform for Progressive Multiple SclerosisA multicentre, interventional, multi-arm, multi-stage trial including randomisation, double blinding, placebo control evaluation of treatments for slowing the progression of disability in participants with Secondary Progressive Multiple Sclerosis (SPMS) and Primary Progressive Multiple Sclerosis (PPMS), together termed Progressive Multiple Sclerosis (PMS)Chataway, Prof JeremyPhase IIINon-commercial portfolio
To evaluate safety and efficacy of ION373 in Alexander Disease  A Phase 1-3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION373 in Patients with Alexander DiseaseChataway, Prof JeremyPhase IIaCommercial portfolio
MS-NIRSNear-infrared spectroscopy to investigate cortical oxygenation and metabolism in multiple sclerosis – an observational cohort pilot study (student study)Chataway, Prof Jeremy Non-commercial non-portfolio
MS-BioBlood Biomarkers in Multiple Sclerosis – a non interventional cohort study (Student Study)Chataway, Prof Jeremy Non-commercial non-portfolio
StarMSA multicentre, randomised controlled trial to evaluate the efficacy of autologous haematopoietic stem cell transplantation versus alemtuzumab or ocrelizumab in relapsing remitting multiple sclerosis. Ciccarelli, Prof Olga Non-commercial portfolio
PITMSPredicting Individual Treatment responses towards personalised medicine in Multiple
Sclerosis
Ciccarelli, Prof OlgaNot ApplicableNon-commercial portfolio
MS and COVID-19 (COVID-19) (Covid, Covid-19 , Coronavirus)Towards understanding the risk of SARS-CoV-2 infection and immune response to COVID-19 vaccines in individuals with immune-mediated conditionsCiccarelli, Prof OlgaNot ApplicableNon-commercial non-portfolio
To study clinical radiological and genetic predictors of outcome in MSUnderstanding the relationship between genotype and neurodegeneration in response to disease modifying treatments in multiple sclerosis: A pilot exploratory study employing high-dimensional inference of existing datasets.Ciccarelli, Prof Olga Non-commercial non-portfolio
ORATORIO HANDA PHASE IIIb MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OCRELIZUMAB IN ADULTS WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSISDe Angelis, Dr FlorianaPhase IIICommercial portfolio
Sodium Accumulation in Multiple sclerosisIn vivo quantification of tissue sodium (23Na) content in the brain and spinal cord in Multiple SclerosisSolanky, Dr Bhavana Non-commercial portfolio
A new prospective Study in Clinically Isolated SyndromeA new prospective Clinical, Genetic and Imaging study of patients with Clinically Isolated Syndrome (CIS).Toosy, Dr Ahmed Non-commercial portfolio

 

Clinical & Movement Neurosciences
Short titleLong titlePIPhaseType
Dystonia Coalition ProjectsDystonia Coalition ProjectsBatla, Dr AmitNot ApplicableNon-commercial non-portfolio
Molecular genetic studies of familial movement disorders.Molecular genetic studies of familial movement disorders.Bhatia, Prof Kailash Non-commercial non-portfolio
SV2a evaluation in neurodegenerative researchSV2a evaluation in neurodegenerative researchBhatia, Prof Kailash Non-commercial portfolio
Synaptic loss in MSAMolecular Imaging of Synaptic loss in Multiple System AtrophyBhatia, Prof KailashNot ApplicableNon-commercial portfolio
Molecular and functional imaging in monogenic PDMolecular and functional imaging in monogenic PDBhatia, Prof KailashNot ApplicableNon-commercial portfolio
Longitudinal Investigation of I2BS in PDLongitudinal Investigation of Imidazoline-2 Binding Site as a Novel Marker of Disease Progression in Parkinson’s Disease: An [11C]BU99008 PET StudyBhatia, Prof KailashNot ApplicableNon-commercial portfolio
Open-Label TD study to evaluate VMAT2 blockade using PETAn Open-label Positron Emission Tomography Study to Evaluate the Effects of Vesicular Monoamine Transporter 2 Receptor (VMAT2) Blockade on the Dopamine Neurotransmitter System in Subjects with Tardive DyskinesiaBhatia, Prof KailashNot ApplicableCommercial non-portfolio
DNMS QuestClinical validation of the Dystonia NMS Questionnaire (DNMS Quest) in patients with primary dystoniaBhatia, Prof Kailash Non-commercial portfolio
Imaging Neuromelanin and Iron in dystonia/parkinsonismImaging Neuromelanin and Iron in dystonia/parkinsonismBhatia, Prof KailashNot ApplicableNon-commercial non-portfolio
ATH434-201A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATH434 IN MULTIPLE SYSTEM ATROPHYChelban , Dr VioricaPhase IIbNon-commercial portfolio
Effort-based decision-making in depression in Parkinson's diseaseEffort-based decision-making, reward, and dopamine in depression in Parkinson’s diseaseCostello, Dr HarryNot ApplicableNon-commercial non-portfolio
PRISM ProjectThe Prevention and Risk Identification of SUDEP (Sudden Unexpected Death in Epilepsy) Mortality - PRISM ProjectDiehl, Dr BeateNot ApplicableNon-commercial non-portfolio
Optimising cognitive outcomes in epilepsy surgeryOptimising cognitive outcomes in epilepsy surgery with direct cortical stimulation: a pilot, feasibility studyDiehl, Dr Beate Non-commercial non-portfolio
Exenatide once-weekly as a treatment for Multiple System Atrophy.A Phase IIa, open label, single-site, 48 week randomised controlled trial evaluating the safety and efficacy of Exenatide once-weekly in the treatment of patients with Multiple System AtrophyFoltynie, Prof ThomasPhase IIaNon-commercial non-portfolio
Phase 3 Trial of exenatide for Parkinson’s diseaseA randomised, double blind, parallel group, placebo controlled, Phase 3 trial of exenatide once weekly over 2 years as a potential disease modifying treatment for Parkinson's disease.Foltynie, Prof ThomasPhase IIINon-commercial portfolio
Kennedy's Disease Study and RegisterKennedy's Disease Study and RegisterGiunti, Dr Paola Non-commercial non-portfolio
EFACTSEuropean Friedreich's Ataxia Consortium for Translational StudiesGiunti, Dr Paola Non-commercial portfolio
Detecting Retinal Changes in ARSACS & Other Ataxias Using OCTDetecting Retinal Changes in Autosomal Recessive Spastic Ataxia of Charlevoix Saguenay (ARSACS) and Other Causes of Ataxia Using Optical Coherence Tomography (OCT)Giunti, Dr Paola Non-commercial portfolio
EUROSCAEuropean integrated project on spinocerebellar ataxias (EUROSCA): pathogenesis, genetics, models and therapyGiunti, Dr Paola Non-commercial portfolio
DRPLA Natural History and Biomarkers Study (DRPLA NHBS), v1.0, 26/4/21Dentatorubral-pallidoluysian atrophy Natural History and Biomarkers Study (DRPLA NHBS)Giunti, Dr PaolaNot ApplicableNon-commercial portfolio
ESMIEuropean Spinocerebellar Ataxia Type 3/Machado-Joseph Disease InitiativeGiunti, Dr Paola Non-commercial portfolio
BP43176 - RO7486967 IN PARTICIPANTS WITH PARKINSON’S DISEASEA PHASE 1B, ADAPTIVE, MULTI-CENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, PARALLEL DESIGN STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF RO7486967 IN PARTICIPANTS WITH EARLY IDIOPATHIC PARKINSON’S DISEASE        Korlipara, Dr PrasadPhase IbCommercial portfolio
Op-TICSDouble blind comparison of optimised Deep Brain Stimulation for severe Tourette syndrome (Op-TICS)Limousin, Prof PatriciaNot ApplicableNon-commercial portfolio
Neurophysiologic assessment of ET patients treated by Vim DBS Assessment of cerebellar ataxia associated with Ventral intermediate median nucleus deep brain stimulation in essential tremor: a multimodal physiologic studyLimousin, Prof Patricia Non-commercial non-portfolio
Brain Sensing in neurological and psychiatric DisordersElectrophysiologic brain sensing using implanted DBS systems in neurological and psychiatric disordersLimousin, Prof PatriciaNot ApplicableNon-commercial non-portfolio
254PD101: Phase 1 Study BIIB094 Administered Intrathecally to AdultsA Phase 1 Single- and Multiple-Ascending-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB094 Administered Intrathecally to Adults With Parkinson’s DiseaseMorris, Prof HuwPhase ICommercial portfolio
262SP101 Phase 1 Study of BIIB101 in Multiple System AtrophyA Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB101 Administered Intrathecally to Adults with Multiple System Atrophy (MSA).Morris, Prof HuwPhase I/IICommercial portfolio
PSP CBD MSA Longitudinal Study UKPROgressive Supranuclear Palsy CorTicoBasal Syndrome Mulitple System Atrophy Longitudinal Study UK (PROSPECTMUK)Morris, Prof Huw Non-commercial portfolio
Parkinson's and Movement Disorders Families Project (PFP)Parkinson's and Movement Disorders Families Project (PFP)Morris, Prof HuwNot ApplicableNon-commercial portfolio
Predict PD the 1000/100/100 pilot studyA pilot study of an algorithm designed to identify Parkinson's disease in the early, nonmotor phase.Noyce, Dr Alastair Non-commercial portfolio
CHIEF-PD STUDYCHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson’s Disease): A phase 3 randomised double-blind placebo-controlled trial of rivastigmine to prevent falls in Parkinson’s diseaseSaifee, Dr TabishPhase IIINon-commercial portfolio
ADepT-PDA Randomised Placebo-Controlled Trial of Escitalopram and Nortriptyline with Standard Psychological Care for Depression in Parkinson’s Disease Saifee, Dr TabishPhase IIINon-commercial portfolio
PPDPredicting Risk of Parkinson’s Disease in the CommunitySchrag, Dr Anette-Eleonore Non-commercial portfolio
POP-PDPatterns of Perception in Parkinson's disease: Understanding the taboo of talking about dementia in Parkinson'sWeil, Dr RimonaNot ApplicableNon-commercial non-portfolio
Vision in Parkinson's DiseaseDisruption of visual processing in Parkinson's DiseaseWeil, Dr Rimona Non-commercial portfolio
Metacognitive function in dementia and Parkinson's diseaseInvestigating metacognition in Alzheimer’s disease and Parkinson’s disease.Weil, Dr Rimona Non-commercial portfolio
TOP HAT Version 1_19.11.19 Trial of Ondansetron as a Parkinson’s HAllucinations TreatmentWeil, Dr RimonaPhase IIbNon-commercial portfolio
The UCL BioResource version 1.The University College London (UCL) BioResource.Wood, Prof NicholasNot ApplicableNon-commercial non-portfolio
NIHR BioResource - Rare DiseasesNational Institute for Health Research BioResource - Rare DiseasesWood, Prof Nicholas Non-commercial portfolio
The effect of weak polarizing currents on the excitability of human motor cortexThe effect of weak polarizing currents on the excitability of human motor cortexRothwell, Prof John Non-commercial non-portfolio
Effect of short bursts of high frequency, low intensity TMS on cortical excitabilityAssessment of the effect of short bursts of high frequency, low intensity TMS on cortical excitability, the corticospinal pathway, and behaviour in healthy subjects and patients with movement disordersRothwell, Prof John Non-commercial non-portfolio

 

Neurosurgery
Short titleLong titlePIPhaseType
ROAR StudyRisk of Aneurysm Rupture StudyGrover, Mr PatrickNot ApplicableNon-commercial portfolio
CARE pilot trialCavernomas A Randomised Effectiveness (CARE) pilot trial, to address the effectiveness of medical management versus medical and surgical management (with neurosurgery or stereotactic radiosurgery) in people with symptomatic brain cavernomaGrover, Mr PatrickNot ApplicableNon-commercial portfolio
AIPGenetics of Endocrine tumoursMarcus, Dr HaniNot ApplicableNon-commercial portfolio
Axonal regeneration using nasal mucosa derived olfactory cells Sourcing specialized olfactory ensheathing cells from nasal mucosal lining of adults to repair spinal cord injuries Marcus, Dr HaniNot ApplicableNon-commercial portfolio
AI in endoscopic transsphenoidal surgeryThe application of Artificial Intelligence to patients undergoing endoscopic transsphenoidal surgery: a single-site prospective feasibility study.Marcus, Dr HaniNot ApplicableNon-commercial non-portfolio
Electrocorticographic Monitoring of Brain Retraction InjuryElectrocorticography as a Neurophysiological Marker for Intraoperative Monitoring of Brain RetractionMarcus, Dr HaniNot ApplicableNon-commercial non-portfolio
Robotic guidance of SEEG electrodes and brain biopsiesUse of Autoguide and EpiNav for directing SEEG electrodes and cranial biopsiesMcEvoy, Mr AndrewNot ApplicableNon-commercial portfolio
Electrical Impedance Tomography & selective stimulation of vagus nerveElectrical Impedance Tomography imaging of functional anatomy and selective stimulation of fascicles within the vagus nerveMcEvoy, Mr AndrewNot ApplicableNon-commercial non-portfolio
Cellular neurobiology of the human brain in health and diseaseExploring the physiology of brain neurons, glia and vasculature in health, and their dysfunction in ischaemia and neurodegenerative diseaseSethi, Dr HumaNot ApplicableNon-commercial non-portfolio
THE SOCIAL CONSEQUENCES OF NEW TECHNOLOGIES IN BRAIN TUMOURSTreatment in a new era of molecular and personalised medicine: Understanding and anticipating the social consequences for people affected by brain tumoursThorne, Mr LewisNot ApplicableNon-commercial portfolio
ICP dynamicsIntracranial Pressure Monitoring in Cerebrospinal Fluid Dynamics disorders: a retrospective observational studyToma, Dr AhmedNot ApplicableNon-commercial non-portfolio
ICP position related changesContinuous body position monitoring in patients undergoing continuous intracranial pressure monitoring, a feasibility studyToma, Dr AhmedNot ApplicableNon-commercial non-portfolio
SC IL-1Ra in SAH - phase III trialDoes Interleukin-1 Receptor Antagonist Improve Outcome following aneurysmal Subarachnoid Haemorrhage (aSAH)? A Phase III trialToma, Dr AhmedPhase IIINon-commercial portfolio
A new prospective Study in Clinically Isolated SyndromeA new prospective Clinical, Genetic and Imaging study of patients with Clinically Isolated Syndrome (CIS).Toosy, Dr AhmedNot ApplicableNon-commercial portfolio
UK Chiari 1 StudyUK Chiari 1 StudyWatkins, Mr LaurenceNot ApplicableNon-commercial non-portfolio
Deep Brain Activity in Cluster Headache and Mood DisorderVentral Tegmental Area Local Field Potentials and Brain Magnetoencephalography Measurement in Cluster Headache and Mood DisorderZrinzo, Mr LudvicNot ApplicableNon-commercial non-portfolio
SVP and ICP AssociationSpontaneous Retinal Venous Pulsation (SVP) and its association with Intracranial Pressure (ICP) in different body
positions
Bremner, Dr FionNot ApplicableNon-commercial non-portfolio
Spontaneous Retinal Venous Pulsation and its correlation with ICPSpontaneous retinal venous pulsation and its correlation with intracranial pressure in patients with cerebrospinal fluid dynamics disturbancesBremner, Dr FionNot ApplicableNon-commercial non-portfolio